Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy

被引：0

作者：

Kim, Tae Min ^{[1
]}

Girard, Nicolas ^{[2
]}

Low, Grace Kah Mun ^{[3
]}

Zhuo, Jianmin ^{[4
]}

Yu, Dae Young ^{[5
]}

Yang, Yishen ^{[4
]}

Murota, Maiko ^{[6
]}

Lim, Cindy Thiow Koon ^{[7
]}

Kleinman, Nora J. ^{[8
]}

Cho, Byoung Chul ^{[9
]}

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Inst Curie, Inst Thorax Curie Montsouris, Paris, France

[3] Johnson & Johnson Int Singapore Pte Ltd, Med Affairs, Janssen Asia Pacif Med Affairs, Singapore, Singapore

[4] Janssen China Res & Dev, Stat & Decis Sci, Beijing, Peoples R China

[5] Janssen Asia Pacific, Real World Evidence, Seoul, South Korea

[6] Janssen Res & Dev, Global Dev, Med Affair Operat, Tokyo, Japan

[7] IQVIA Solut Asia Pte Ltd, Real World Solut, Singapore, Singapore

[8] IQVIA Hong Kong, Real World Solut, Kwai Fong, Hong Kong, Peoples R China

[9] Yonsei Univ, Dept Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

来源：

ACTA ONCOLOGICA | 2023年

关键词：

CHRYSALIS trial; external control; LC-SCRUM-Asia; amivantamab; EGFR exon 20 insertions; MOLECULAR HETEROGENEITY; CLINICAL-RESPONSE; ADENOCARCINOMAS;

D O I：

10.1080/0284186X.2023.2254479

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan. Patients and methods: External control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR). Results: One hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09months, HR [95% CI] 0.59 [0.40-0.88]), PFS (median PFS 6.74 vs 4.73months, HR 0.59 [0.45-0.78]), TTNT (median TTNT 12.16 vs 5.09months, HR 0.39 [0.29-0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n=61) showed similar clinical benefits. Conclusion: In the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies.

引用

页码：1689 / 1697

页数：9

共 43 条

[1] EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Arcila, Maria E.
Nafa, Khedoudja
Chaft, Jamie E.
Rekhtman, Natasha
Lau, Christopher
Reva, Boris A.
Zakowski, Maureen F.
Kris, Mark G.
Ladanyi, Marc
[J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) : 220 - 229
[2] EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)
Cardona, Andres F.
Rojas, Leonardo
Lucia Zatarain-Barron, Zyanya
Freitas, Helano C.
Granados, Sara T.
Castillo, Omar
Oblitas, George
Corrales, Luis
Castro, Christian D.
Ruiz-Patino, Alejandro
Martin, Claudio
Angelina Perez, Maria
Gonzalez, Lisde
Chirinos, Luis
Vargas, Carlos
Carranza, Hernan
Otero, Jorge
Rodriguez, July
Rodriguez, Jenny
Archila, Pilar
Lema, Mauricio
Acosta Madiedo, Jose
Karachaliu, Niki
Wills, Beatriz
Pino, Luis E.
de Lima, Vladimir
Rosell, Rafael
Arrieta, Oscar
[J]. LUNG CANCER, 2018, 125 : 265 - 272
[3] The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer
Chansky, Kari
Detterbeck, Frank C.
Nicholson, Andrew G.
Rusch, Valerie W.
Vallieres, Eric
Groome, Patti
Kennedy, Catherine
Krasnik, Mark
Peake, Michael
Shemanski, Lynn
Bolejack, Vanessa
Crowley, John J.
Asamura, Hisao
Rami-Porta, Ramon
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (07) : 1109 - 1121
[4] Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
Chen, Dan
Song, Zhengbo
Cheng, Guoping
[J]. ONCOTARGETS AND THERAPY, 2016, 9 : 4181 - 4186
[5] Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Choudhury, Noura J.
Schoenfeld, Adam J.
Flynn, Jessica
Falcon, Christina J.
Rizvi, Hira
Rudin, Charles M.
Kris, Mark G.
Arcila, Maria E.
Heller, Glenn
Yu, Helena A.
Ladanyi, Marc
Riely, Gregory J.
[J]. CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2920 - 2927
[6] Collins LG, 2007, AM FAM PHYSICIAN, V75, P56
[7] Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, P1, DOI 10.1007/978-1-4419-0685-4_1
[8] Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Floc'h, Nicolas
Martin, Matthew J.
Riess, Jonathan W.
Orme, Jonathan P.
Staniszewska, Anna D.
Menard, Ludovic
Cuomo, Maria Emanuela
O'Neill, Daniel J.
Ward, Richard A.
Finlay, M. Raymond V.
McKerrecher, Darren
Cheng, Mingshan
Vang, Daniel P.
Burich, Rebekah A.
Keck, James G.
Gandara, David R.
Mack, Philip C.
Cross, Darren A. E.
[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 885 - 896
[9] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Gazdar, A. F.
[J]. ONCOGENE, 2009, 28 : S24 - S31
[10] Goto K., 2017, Annals Oncol, V28, pix5, DOI [10.1093/annonc/mdx570.001, DOI 10.1093/ANNONC/MDX570.001]

← 1 2 3 4 5 →